Principal Office

DREEBIT GmbH
Zur Wetterwarte 50
D-01109 Dresden
Germany
Phone: (+)49 - 35 12 15 91 84
Fax: (+)49 - 35 12 15 91 86
E-Mail: info@dreebit.com
Web: www.dreebit.com

Contact Person

Ass.Prof. Dr. Günter ZSCHORNACK
CTO
Phone: (+)49 – 351 260 2212
Fax: (+)49 - 35 12 15 91 86
E-Mail: günter.zschornack@dreebit.com

The DREEBIT GmbH focuses its activities on the development, fabrication, service, sales and distribution of ion sources and irradiation facilities, electron beam techniques, equipment for micro- and nanotechnology and ion sources for the medical particle therapy.

The DREEBIT GmbH provides room-temperature EBIT/EBIS ion sources for the production of highly charged ions but also complete irradiation facilities featuring the available EBIT/EBIS ion sources. These ion sources produce ions of practically all elements of almost all ion charge states as well as beams of low charged molecular fragments. The offered ion beam facility provides ion beams with diameters of mm down to some hundreds of µm. Thereby the ion beam energies range from about 1.5 MeV down to about 10 eV x q (q- ion charge state). Available are pulsed beams with pulse widths of 2 µs up to 40 µs as well as continuous ion beams (the so-called dc or leaky mode).

A new generation of powerful ion sources for medical applications (particle therapy) and other high-tech applications will be available in 2008. This type of ion sources, the so-called Dresden EBIS-SC, is a superconducting ion source which is based on the most modern principles of refrigeration technology as well as electron-beam technology. The Dresden EBIS-SC is expected to produce bare ions up to elements of Z=40 and to deliver ion pulses of C^{6+} with up to 3 x 10^9 ions as it is needed for the use in particle therapy.

World-wide target customers are scientific institutes (universities, national research centers, industrial research) of various fields of interest such as solid-state physics, surface analytics (TOF-SIMS, LEAP, FIB, …), atomic physics, fusion research, radiation biology and medicine. The most promising target customer group are companies of the high technology sector and of medical technology.